Epidemiology of liver transplantation and post-LT complications in Germany: nationwide study (2005-2018).


Journal

European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874

Informations de publication

Date de publication:
01 11 2023
Historique:
medline: 21 11 2023
pubmed: 19 9 2023
entrez: 19 9 2023
Statut: ppublish

Résumé

To date, liver transplantation (LT) is the only curative treatment for cirrhosis and early-diagnosed progressive acute liver failure (ALF). However, LT results in morbidities and mortality even post-LT. Different comorbidities may follow and further increase mortality and morbidity. In this study, we investigated the outcomes and their trends over a period of 14 years among hospitalized patients evaluated for LT, transplant and post-LT in Germany. This German nationwide study investigated the number of admissions of patients hospitalized for evaluation of LT and post-LT on related comorbidities and complications between 2005 and 2018 based on the DRG system with ICD-10/OPS codes. 14 745 patients were put on the LT waiting list and 12 836 underwent LT during the observational period. The LT number decreased by 2.3% over time, while the waiting list mortality rate increased by 5%. By contrast, the in-hospital mortality rate decreased by 3%, especially in ALF patients (decrease of 16%). Interestingly, admissions of post-LT patients for complications almost doubled, driven mainly by complications of immunosuppression (tripled). Importantly, post-LT patients with acute kidney injury (20.2%) and biliodigestive anastomosis (18.4%) showed the highest in-hospital mortality rate of all complications. In conclusion, the decrease in LT leads most probably to the increased in-hospital mortality of patients on the waiting list. Interestingly, in-hospital mortality decreased in LT patients. Post-LT comorbidities requiring hospitalization increased in the observational period and management of patients post-LT with AKI or biliodigestive anastomosis should be addressed.

Sections du résumé

BACKGROUND
To date, liver transplantation (LT) is the only curative treatment for cirrhosis and early-diagnosed progressive acute liver failure (ALF). However, LT results in morbidities and mortality even post-LT. Different comorbidities may follow and further increase mortality and morbidity. In this study, we investigated the outcomes and their trends over a period of 14 years among hospitalized patients evaluated for LT, transplant and post-LT in Germany.
METHODS
This German nationwide study investigated the number of admissions of patients hospitalized for evaluation of LT and post-LT on related comorbidities and complications between 2005 and 2018 based on the DRG system with ICD-10/OPS codes. 14 745 patients were put on the LT waiting list and 12 836 underwent LT during the observational period.
RESULTS
The LT number decreased by 2.3% over time, while the waiting list mortality rate increased by 5%. By contrast, the in-hospital mortality rate decreased by 3%, especially in ALF patients (decrease of 16%). Interestingly, admissions of post-LT patients for complications almost doubled, driven mainly by complications of immunosuppression (tripled). Importantly, post-LT patients with acute kidney injury (20.2%) and biliodigestive anastomosis (18.4%) showed the highest in-hospital mortality rate of all complications.
CONCLUSION
In conclusion, the decrease in LT leads most probably to the increased in-hospital mortality of patients on the waiting list. Interestingly, in-hospital mortality decreased in LT patients. Post-LT comorbidities requiring hospitalization increased in the observational period and management of patients post-LT with AKI or biliodigestive anastomosis should be addressed.

Identifiants

pubmed: 37724476
doi: 10.1097/MEG.0000000000002640
pii: 00042737-202311000-00008
pmc: PMC10538604
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1289-1297

Informations de copyright

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

Références

Durand F, Pavesi M, Cheung R. Liver transplantation for non-alcoholic steatohepatitis in Europe: where do we stand? J Hepatol 2019; 71:240–242.
Olivo R, Guarrera JV, Pyrsopoulos NT. Liver transplantation for acute liver failure. Clin Liver Dis 2018; 22:409–417.
Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007; 102:2459–2463.
Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol 2013; 10:434–440.
Tacke F, Kroy DC, Barreiros AP, Neumann UP. Liver transplantation in Germany. Liver Transpl 2016; 22:1136–1142.
Richter-Kuhlmann E. Überprüfung der Lebertransplantationszentren: Deutliche Verstöße in vier Zentren. Dtsch Arztebl Int 2013; 110:A-1663-A-1664.
Loosen SH, Bock HH, Hellmich M, Knoefel WT, Trautwein C, Keitel V, et al. Hospital mortality and current trends in liver transplantation in Germany—a systematic analysis of standardized hospital discharge data, 2008–2017. Dtsch Arztebl Int 2021; 118:497–502.
Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut 2009; 58:452–463.
Gu W, Hortlik H, Erasmus HP, Schaaf L, Zeleke Y, Uschner FE, et al. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Reg Health Eur 2022; 12:100240.
Shaw D, Neuberger J, Murphy P. Lessons from the German Organ Donation Scandal. J Intensive Care Soc 2013; 14:200–201.
Bernal W, Wendon J. Acute liver failure. N Engl J Med 2013; 369:2525–2534.
Saliba F, Bañares R, Larsen FS, Wilmer A, Parés A, Mitzner S, et al. Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts. Intensive Care Med 2022; 48:1352–1367.
Saliba F, Duvoux C, Dharancy S, Dumortier J, Calmus Y, Gugenheim J, et al. Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study. Liver Int 2022; 42:2513–2523.
Toti L, Manzia TM, Blasi F, Lenci I, Baiocchi L, Toschi N, et al. Renal function, adherence and quality of life improvement after conversion from immediate to prolonged-release tacrolimus in liver transplantation: prospective ten-year follow-up study. Transpl Int 2022; 35:10384.
Duvoux C, Pageaux GP. Immunosuppression in liver transplant recipients with renal impairment. J Hepatol 2011; 54:1041–1054.
Charlton M, Levitsky J, Aqel B, OʼGrady J, Hemibach J, Rinella M, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation 2018; 102:727–743.
Kochhar G, Parungao JM, Hanouneh IA, Parsi MA. Biliary complications following liver transplantation. World J Gastroenterol 2013; 19:2841–2846.
Craig EV, Heller MT. Complications of liver transplant. Abdom Radiol (NY) 2021; 46:43–67.
El-Meteini M, Hamza A, Abdalaal A, Fathy M, Bahaa M, Mukhtar A, et al. Biliary complications including single-donor mortality: experience of 207 adult-to-adult living donor liver transplantations with right liver grafts. HPB (Oxford) 2010; 12:109–114.
Abu-Gazala S, Olthoff KM. Current status of living donor liver transplantation in the United States. Annu Rev Med 2019; 70:225–238.
Chen R, Yi H, Zhen J, Fan M, Xiao L, Yu Q, et al. Donor with HLA-C2 is associated with acute rejection following liver transplantation in Southern Chinese. HLA 2022; 100:133–141.
Kohli DR, Desai MV, Kennedy KF, Pandya P, Sharma P. Patients with post-transplant biliary strictures have significantly higher rates of liver transplant failure and rejection: a nationwide inpatient analysis. J Gastroenterol Hepatol 2021; 36:2008–2014.
Huebener P, Sterneck MR, Bangert K, Drolz A, Lohse AW, Kluge S, et al. Stabilisation of acute-on-chronic liver failure patients before liver transplantation predicts post-transplant survival. Aliment Pharmacol Ther 2018; 47:1502–1510.

Auteurs

Wenyi Gu (W)

Department of Internal Medicine B, University Hospital Muenster, Muenster.
Department of Internal Medicine I, University Hospital Frankfurt, Goethe University Frankfurt.

Louisa Schaaf (L)

Department of Internal Medicine I, University Hospital Frankfurt, Goethe University Frankfurt.

Hannah Hortlik (H)

Department of Internal Medicine I, University Hospital Frankfurt, Goethe University Frankfurt.

Yasmin Zeleke (Y)

Department of Internal Medicine I, University Hospital Frankfurt, Goethe University Frankfurt.

Maximilian J Brol (MJ)

Department of Internal Medicine B, University Hospital Muenster, Muenster.

Andreas A Schnitzbauer (AA)

Department of General, Visceral, Transplant and Thoracic Surgery, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main.

Wolf O Bechstein (WO)

Department of General, Visceral, Transplant and Thoracic Surgery, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main.

Stefan Zeuzem (S)

Department of Internal Medicine I, University Hospital Frankfurt, Goethe University Frankfurt.

Alexander Queck (A)

Department of Internal Medicine I, University Hospital Frankfurt, Goethe University Frankfurt.

Kai-Henrik Peiffer (KH)

Department of Internal Medicine B, University Hospital Muenster, Muenster.
Department of Internal Medicine I, University Hospital Frankfurt, Goethe University Frankfurt.

Michael Tischendorf (M)

Department of Internal Medicine B, University Hospital Muenster, Muenster.

Andreas Pascher (A)

Department of General, Visceral, Transplant and Thoracic Surgery, University Hospital Muenster, Muenster, Germany.

Wim Laleman (W)

Department of Internal Medicine B, University Hospital Muenster, Muenster.
Department of Gastroenterology & Hepatology, Section of Liver and Biliopancreatic Disorders, University Hospitals of Leuven, KU Leuven, Leuven, Belgium.

Michael Praktiknjo (M)

Department of Internal Medicine B, University Hospital Muenster, Muenster.

Martin S Schulz (MS)

Department of Internal Medicine B, University Hospital Muenster, Muenster.

Frank E Uschner (FE)

Department of Internal Medicine B, University Hospital Muenster, Muenster.

Florian Rennebaum (F)

Department of Internal Medicine B, University Hospital Muenster, Muenster.

Jonel Trebicka (J)

Department of Internal Medicine B, University Hospital Muenster, Muenster.
European Foundation for Study of Chronic Liver Failure, Barcelona, Spain.
Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH